Lyra Therapeutics Inc (LYRA) - Total Assets
Based on the latest financial reports, Lyra Therapeutics Inc (LYRA) holds total assets worth $36.11 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lyra Therapeutics Inc - Total Assets Trend (2018–2025)
This chart illustrates how Lyra Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see LYRA market cap overview for the company's overall valuation and market capitalisation.
Lyra Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Lyra Therapeutics Inc's total assets of $36.11 Million consist of 45.1% current assets and 54.9% non-current assets. Review Lyra Therapeutics Inc debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 44.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Lyra Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Lyra Therapeutics Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lyra Therapeutics Inc's current assets represent 45.1% of total assets in 2025, a decrease from 98.3% in 2018.
- Cash Position: Cash and equivalents constituted 44.0% of total assets in 2025, down from 94.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Lyra Therapeutics Inc Competitors by Total Assets
Key competitors of Lyra Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $547.14 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
SHG:688266
|
China | CN¥3.01 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Galecto Inc
NASDAQ:GLTO
|
USA | $535.44 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.53 Billion |
Lyra Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.71 | 3.41 | 16.15 |
| Quick Ratio | 1.71 | 3.41 | 16.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.75 Million | $30.39 Million | $63.18 Million |
Lyra Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Lyra Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.10 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -45.6% |
| Total Assets | $36.11 Million |
| Market Capitalization | $337.23K USD |
Valuation Analysis
Below Book Valuation: The market values Lyra Therapeutics Inc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lyra Therapeutics Inc's assets decreased by 45.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lyra Therapeutics Inc (2018–2025)
The table below shows the annual total assets of Lyra Therapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $36.11 Million | -45.58% |
| 2024-12-31 | $66.35 Million | -53.47% |
| 2023-12-31 | $142.60 Million | +29.67% |
| 2022-12-31 | $109.97 Million | +100.43% |
| 2021-12-31 | $54.87 Million | -32.12% |
| 2020-12-31 | $80.83 Million | +440.20% |
| 2019-12-31 | $14.96 Million | -41.00% |
| 2018-12-31 | $25.36 Million | -- |
About Lyra Therapeutics Inc
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-infla… Read more